Cellular therapies in no-option critical limb ischemia: present status and future directions
Kwiatkowski T., Zbierska-Rubinkiewicz K., Krzywoń JW., Szkółka Ł., Kuczmik W., Majka M.
Randomized Controlled Trial on Peripheral Artery Disease, published in Postepy Kardiol Interwencyjnej (2022) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Randomized Controlled Trial
- Journal
- Postepy Kardiol Interwencyjnej (2022)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 36967860
- PMCID
- PMC10031679
- DOI
- 10.5114/aic.2022.120962
- Citations
- 4
Abstract (original English)
Critical limb ischemia - an advanced stage of lower extremity arterial disease with presence of rest pain and/or ischemic ulcers - remains an important cause of major amputations and disability in developed societies. Novel treatment strategies are urgently needed to prevent (or delay) amputations in particular for patients in whom effective revascularization is no longer feasible for anatomic and/or technical reasons (no-option critical limb ischemia - N-O CLI). Cellular therapies have been gaining the growing attention of researchers and clinicians in the last two decades. Several cell types have been used in pre-clinical and clinical studies, and a number of mechanisms have been proposed to contribute to vascular reparation and regeneration in N-O CLI. Although early trials suggested clinical improvement with use of cell-based therapies in N-O CLI, meta-analyses that included randomized controlled trials have not provided definitive conclusions. Fundamental limitations have involved poorly defined cell lines/populations, limited numbers of study participants and limited follow-up periods, and enrolling patients "too sick to benefit" (such as those in Rutherford class 6). Recent advances include standardized "unlimited" sources of therapeutic cells and better understanding of mechanisms that may contribute to vascular reparation and regeneration. Furthermore, based on recent
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level AMeta-analysisEurope PMC
Cellular therapy for the peripheral arterial disease treatment: Protocol for a systematic review and meta-analysis
Meta-analysis on Peripheral Artery Disease, published in PLoS One (2025) — summary generated from the PubMed abstract.
- 2025
PLoS One1 citations - Level ASystematic ReviewPubMed
The Efficacy of Stem Cells in Wound Healing: A Systematic Review.
Systematic Review on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Int J Mol Sci (2024) — summary generated from the PubMed abstract.
- 2024
Int J Mol Sci60 citations - Level AMeta-analysisEurope PMC
The Immune-Centric Revolution Translated into Clinical Application: Peripheral Blood Mononuclear Cell (PBMNC) Therapy in Diabetic Patients with No-Option Critical Limb-Threatening Ischemia (NO-CLTI)-Rationale and Meta-An
Meta-analysis on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in J Clin Med (2024) — summary generated from the PubMed abstract.
- 2024
J Clin Med2 citations - Level ASystematic ReviewEurope PMC
A systematic review of patient-reported outcome measures patients with chronic limb-threatening ischemia
Systematic Review on Peripheral Artery Disease, published in J Vasc Surg (2022) — summary generated from the PubMed abstract.
- 2022
J Vasc Surg23 citations - Level AMeta-analysisEurope PMC
Autologous Stem Cell Therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials
Meta-analysis with a reported sample of 1096 on Peripheral Artery Disease, Chronic Wound, published in Cells (2021) — summary generated from the PubMed abstract.
- 2021
- n = 1096
Cells19 citations - Level ARandomized Controlled TrialPubMed
Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF).
Randomized Controlled Trial with a reported sample of 114 on Diabetic Foot, Peripheral Artery Disease, Chronic Wound, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.
- 2019
- n = 114
Stem Cell Res Ther57 citations